Sanofi, Advent finally shake hands on $2.2B European generics sale

It’s official: Sanofi is finally ready to unload its European generics business.

More than two months after disclosing that they were in exclusive talks, the French drugmaker and buyer Advent International have ironed out the details on a €1.9 billion sale of the unit, dubbed Zentiva.